California-based AI biotech company Terray Therapeutics has received an undisclosed amount of equity investment from NVIDIA's venture arm, NVentures, with participation from new and existing institutional investors, including John Maraganore, the founding CEO of Alnylam Pharmaceuticals, and Bassil Dahiyat, the founder and CEO of Xencor.
The proceeds will be used to focus on enhancing small molecule drug discovery by leveraging NVIDIA’s models, NVIDIA DGX Cloud and BioNeMo, and advanced AI software.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.